Format

Send to

Choose Destination
Clin Exp Med. 2018 Nov;18(4):555-562. doi: 10.1007/s10238-018-0517-2. Epub 2018 Jul 9.

A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung.

Author information

1
Department of Pulmonary Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, Henan, China.
2
Department of Pulmonary Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, Henan, China. Xinglihuazzu@163.com.
3
Department of Pathology, Anyang Tumor Hospital, Anyang, 455000, Henan, China.

Abstract

The aim was to investigate the clinicopathological characteristics, diagnosis, and prognosis of sarcomatoid carcinoma of the lung. We reviewed 114 cases of sarcomatoid carcinoma of the lung in patients that were admitted to the First Affiliated Hospital of Zhengzhou University and Anyang Tumor Hospital from January 2009 to March 2018. We analyzed the clinical characteristics, immunohistochemical profiles, treatments, and overall survival of the patients. The patient population included 88 men and 26 women. Median patient age was 65 years (range 37-88 years), and the gender ratio (M/F) was 3.4:1. Median survival was 3.5 months (range 0.5-60 months). Univariate analysis showed that tumor location, tumor size, M stage, TNM stage, chemotherapy, and surgery were all prognostic factors for survival (P < 0.05). We found that T stage, surgery, and chemotherapy were independent prognostic factors for sarcomatoid carcinoma (P < 0.05). Pulmonary sarcomatoid carcinoma is a rare tumor with a poor prognosis. Patients with smaller T stage, complete resection, and chemotherapy exhibited a better prognosis. Early diagnosis and early treatment are important to improve the prognosis of these patients.

KEYWORDS:

Clinical pathology; Lung cancer; Sarcomatoid carcinoma; Survival analysis; Treatment response

PMID:
29987681
DOI:
10.1007/s10238-018-0517-2

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center